Is CRIS or CRSP more undervalued in 2026?

CirclFi compares Curis, Inc. (CRIS) and CRISPR Therapeutics AG (CRSP) using 13 institutional-grade valuation models. CRIS has a Quality of Company score of 5.0/10 while CRSP scores 6.2/10.

Which is a better buy — CRIS or CRSP?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CRIS and CRSP valuations compare?

CRIS at $0.52 and CRSP at $56.38 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CRIS vs CRSP Valuation Comparison 2026 — Intrinsic Value Analysis

CRIS

Biotechnology

Curis, Inc.

Quality

5.0

out of 10

Value Trap

LOW

Price

$0.52

Last close

Models

9/13

Active

CRSP

Biotechnology

CRISPR Therapeutics AG

Quality

6.2

out of 10

Value Trap

SAFE

Price

$56.38

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	CRIS Fair Value	CRIS Upside	CRSP Fair Value	CRSP Upside
Bayesian DCF	Intrinsic	$0.25	-51.6%	$10.94	-80.6%
Earnings Power Value	Intrinsic	—	—	$27.66	-43.3%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$0.34	-35.8%	$1.13	-97.8%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CRIS vs CRSP — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CRIS vs CRSP — Which Stock Is More Undervalued?

CRSP scores higher with a 6.2/10 quality rating vs CRIS's 5.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Curis, Inc. (CRIS) and CRISPR Therapeutics AG (CRSP) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CRIS currently trades at $0.52 with a QOC of 5.0/10, while CRSP trades at $56.38 with a QOC of 6.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).